Login to Your Account



Trimeris, Roche Fusion Inhibitor Succeeds In Phase III HIV Trial

By Kim Coghill


Friday, April 19, 2002
A fusion inhibitor for HIV patients being developed by Trimeris Inc. and Hoffmann-La Roche Inc. produced better than expected results in a Phase III trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription